Kristin Hopper
Family · Visalia, CANPI 1831496116
Payments from drug & device makers
Across 266 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$959
- Johnson & Johnson$828
- GSK$413
- AstraZeneca$342
- Mallinckrodt Hospital Products Inc.$172
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,80798%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,159 |
| Amgen(2 entities) | 58 | $959 |
| Johnson & Johnson | 71 | $828 |
| GSK | 12 | $413 |
| AstraZeneca(2 entities) | 9 | $342 |
| Mallinckrodt Hospital Products Inc. | 3 | $172 |
| Novartis | 8 | $166 |
| UCB, Inc. | 5 | $163 |
| Aurinia Pharma U.S., Inc. | 2 | $145 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $118 |
| Pfizer | 5 | $90 |
| Boehringer Ingelheim | 3 | $63 |
| Lilly USA, LLC | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Alvogen Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,906 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 54 | $394,050 |
| Humira(Cf) PenAdalimumab | 45 | $334,717 |
| RinvoqUpadacitinib | 51 | $312,352 |
| Xeljanz XrTofacitinib Citrate | 24 | $131,421 |
| ActemraTocilizumab | 16 | $74,500 |
| Humira(Cf)Adalimumab | 11 | $73,952 |
| OtezlaApremilast | 21 | $72,329 |
| SimponiGolimumab | 11 | $65,737 |
| RasuvoMethotrexate/Pf | 12 | $7,424 |
| MethotrexateMethotrexate Sodium | 283 | $5,509 |
| Hydroxychloroquine Sulfate | 100 | $4,221 |
| Mycophenolate Mofetil | 23 | $3,371 |
| Azathioprine | 70 | $2,732 |
| Diclofenac Sodium | 90 | $1,673 |
| Pregabalin | 51 | $1,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,159 | $386,30462 claims |
| AmgenOtezla | $959 | $72,32921 claims |
| Johnson & JohnsonSimponi | $828 | $65,73711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Visalia
- Pamela ScottVisalia$165K
- Maribel TorresVisalia$57K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.